ArticleClinicoEconomics and outcomes research : CEOR2026

The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia.

Nada Abu-Shraie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.